Artificial intelligence-based tool being tested to predict adverse kidney events in patients with COVID-19
The artificial intelligence-enabled clinical diagnostic for kidney disease, known as KidneyIntelX, will be used in a study to determine its predictive ability to assess the risk of adverse kidney events in patients diagnosed with COVID-19, according to a press release from RenalytixAI.
The utility of the device in this context is being examined by investigators from the Icahn School of Medicine at Mount Sinai in a study of patients admitted to Mount Sinai with the virus. The motivation to conduct the Prediction of Major Adverse Kidney Events and Recovery study comes from the high number of cases in the New York metropolitan area, with the Mount Sinai Hospital and the Mount Sinai Health System being “severely affected by the enormous caseload of COVID-19” beginning in March, according to the release.
The need for a tool to predict adverse kidney events is further evidenced by the poor observed outcomes, with the release noting that patients with acute and chronic kidney disease may experience more severe adverse outcomes with COVID-19 and that acute kidney injury occurs in approximately 20% of patients hospitalized with the virus. Furthermore, the release stated that patients who develop AKI after admission for COVID-19 have a mortality rate that is two to seven times higher than that of patients without AKI.
Investigators will focus on clinical features and biomarkers including “multiple plasma biomarkers and urine proteomics and RNA sequences.” Blood samples that have been collected from patients admitted to the hospital since early April will be used in the research.
“Given the evidence that there is extensive systemic inflammation, as well as kidney tubular injury in patients with COVID-19, the KidneyIntelX platform is well positioned to play a prominent role in understanding which patients are at highest risk of severe kidney complications and which patients are more likely to experience longer-term detrimental effects of COVID-19 infection,” Steven Coca, MD, co-founder of RenalytixAI and co-investigator on the study, said in the release.